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ABSTRACT 
The main objective of this review is to highlight and explore the inter-relationship and the 
functioning of the intellectual property right in the pharmaceutical and biotechnology 
industry. The rising tide of patent applications can be witnessed globally in this industry as 
the need for such protection and licensing has become imperative so as to safeguard the rights 
of the inventor and also to encourage and promote new talents, inventions and innovations 
which can be a boon for the economy. The field of biotechnology is an upcoming science 
which is still at the initial stage of establishing  a foundation but it promises a revolution in 
the fields of  medicine, agriculture, pharmaceuticals  and  industrial  sector  amongst  other  
sectors  of  the  economy  along  with contribution to the GDP growth.    
GRAPHICAL ABSTRACT 
                            
INTRODUCTION  
Intellectual property refers to the exclusive rights granted by the State over creations of the 
human mind, in particular, inventions, literary and artistic works, distinctive signs and 
designs used in commerce. Intellectual property is divided into two main categories: 
industrial property rights, which include patents, utility models, trademarks, industrial 
designs, trade secrets, new varieties of plants and geographical indications; and copyright and 
related rights, which relate to literary and artistic works. 
Industrial property (IP) rights are extremely important for the pharmaceutical industry. The 
use of the IP system by SMEs in the pharmaceutical industry depends largely on the business 
strategy of a company, its size, resources, innovative capacity, competitive context and field 
of expertise. Research-based, innovation-led companies that seek to develop new drugs 
improve or adapt existing drugs or develop new pharmaceutical/medical equipment or 
processes, tend to rely heavily on the patent system to ensure they recover the investments 
incurred in research and development. Companies that rely on licensing in or licensing out of 
pharmaceutical products will need to be knowledgeable about the patent system to so that 
they are able to negotiate fair and balanced licensing contracts. SMEs in the pharmaceutical 
industry may use the wealth of information contained in patent documents as a crucial input 
to their R&D work, to get ideas for further innovation, to ensure their "freedom to operate" or 
to find out when a patent is due to expire opening the door for the introduction of generics. 
Confidential information, protected as trade secrets, is also important for many companies, as 
is the valuable know-how or undisclosed test data relating to new or improved drugs. 
Understanding the trademark system is important for companies selling branded products. 
Industrial designs, plant variety protection and copyright and related rights are generally less 
relevant to most SMEs in the pharmaceutical sector but this could vary depending on the 
product line and strategy of each company. 
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) provides 
for minimum norms and standards in respect of the following categories of intellectual 
property rights: - 
a. Copyrights and related rights 
b. Trademarks 
c. Geographical Indications 
d. Industrial Designs 
e. Patents 
f. Lay out designs of integrated circuits 
g. Protection of undisclosed information (trade secrets) 
The Agreement sets out minimum standards to be adopted by the parties, though they are free 
to provide higher standards of protection. A transition period of five years is available to all 
developing countries to give effect to the provisions of the TRIPS Agreement. This period 
ended on 1.1.2000. No transitional period is available, however, for grant of national 
treatment and most-favoured-nation treatment. Countries that did not provide product patents 
in certain areas of technology as on 1.1.1995, can delay the grant of product patents in those 
areas for another five years i.e. upto 1.1.2005. 
 
Where a country does not make available patent protection for pharmaceutical and 
agricultural chemical products as on 1.1.1995, they have to provide a means for accepting 
applications for such inventions (mailbox), apply applicable priority rights and provide 
exclusive marketing rights (EMRs) for such products. The EMRs have to be provided in 
India only if a set of conditions have been met, i.e. where a patent application has been filed 
after 1.1.1995 in any WTO Member, patent and marketing approval granted in that Member 
country, an application has been filed in the mailbox in India and marketing approval 
obtained in India. The EMR is available for five years from grant or till the patent is granted 
or rejected, whichever is earlier. The Patent (Amendment) Act, 1999 was passed in March 
1999 to provide for mailbox and EMR facility. The state of play 
of India’s obligations under TRIPS arising as on 1.1.2000 in respect of the seven IPRs 
covered under TRIPS is briefly given below1-5. 
(a) Copyrights and related rights 
In the area of copyright and related rights (i.e. rights of performers, producers of phonograms 
and broadcasting organizations), the Agreement requires compliance with the substantive 
provisions of the Berne Convention. Computer programmes are to be protected as literary 
works, the term of protection for copyrights and right of performers and producers of 
phonograms is to be no less than 50 years. In case of broadcasting organisations, however, 
the term of protection is to be at least 20 years. India is already a signatory to the Berne 
Convention and our laws conform to the provisions of the Convention. India’s copyright law 
has been amended and in some ways exceeds the requirements of the TRIPS Agreement, for 
example, on the period for copyright protection (which is 60 years in India). The law was 
amended in December 1999 to grant 25-year term of protection for neighbouring rights. 
(b) Trademarks  
The Trade and Merchandise Marks Act 1958 was in its essential features in accordance with 
TRIPS, except that it did not cover service marks in its scope. This has been done by 
replacing it with the Trademarks Act 1999. We are now fully compliant with our TRIPS 
obligations.  
(c) Geographical Indication 
The Agreement contains a general obligation that parties shall provide the legal means for 
interested parties to prevent the use of any means in the designation or presentation of a good 
that indicates or suggests that the good in question originates in a geographical area other that 
the true place of origin of the good. We currently provide protection to geographical 
indications through passing off action in courts or through certification marks. However, to 
provide better protection to geographical indications a new law "The Geographical Indication 
of Goods (Registration & Protection) Act, 1999 has since been enacted.  
 
(d) Industrial Designs 
Obligations envisaged in respect of industrial designs are that independently created designs 
that are new or original shall be protected. There in an option to exclude from protection, 
designs dictated by technical or functional consideration, as against aesthetic consideration 
which constitutes the coverage of industrial designs. 
(e)Patents 
The basic obligation in the area of patents is that, inventions in all fields of technology 
whether products or processes shall be patentable if they meet the three tests of being novel, 
involving an inventive step and being capable of industrial application. In addition to the 
general security exception, which applies to the entire TRIPS Agreement, specific exclusions 
are permissible from the scope of patentability. These are available in the areas of inventions 
whose commercial exploitation is to be prevented to protect public order or morality, human, 
animal plant life or health or to avoid serious prejudice to the environment. In addition, we 
can exclude from patentability diagnostic, therapeutic and surgical methods for the treatment 
of human and animals, plants and animals other than microorganisms, and essentially 
biological process for the production of plants and animals other than non-biological 
processes. 
 
To meet our TRIPS obligations as on 1.1.2000, the Patents (Second Amendment) Bill, 1999 
has been introduced in the Parliament in December 1999 and is before the Joint Committee of 
theHouses. 
 
In respect of plant varieties, there is an obligation to provide for protection either by patents 
or by an effective sui generis system or by any combination thereof. The Agreement does not 
spell out the elements of an effective sui generis system and it is left to each Government to 
determine the elements, which could be deemed to be providing effective protection. A 
decision has been taken to put in place a sui generis system as it is perceived to be in our 
national interest. A Bill in this regard is before the Joint Committee of the Houses of the 
Parliament. 
 Patentable subject matter- 
 Under many national laws, patentable subject matter is defined negatively, i.e. by 
providing a list of what cannot be patented. However, there are important differences 
between countries in terms of what may represent unpatentable subject matter. For example, 
patent legislation in some countries includes some of the following as unpatentable subject 
matter: 
 Discoveries and scientific theories; 
 Aesthetic creations (which may be protected by industrial designs); 
 Schemes, rules and methods for performing mental acts; 
 Newly discovered substances as they naturally occur in the world; 
 Inventions the exploitation of which is contrary to "public order" or morality; 
 Diagnostic, therapeutic and surgical methods of treatment for humans or animals (but 
not products for use in such methods); 
 Plants and animals other than microorganisms, and essentially biological processes 
for the production of plants or animals other than non-biological and microbiological 
processes. 
In the pharmaceutical industry, types of inventions that are patentable in many countries (as 
long as the other criteria are met) include new pharmaceutical compounds, new or improved 
products for diagnostics, new dosage forms of known therapeutics, microorganisms, novel 
combinations of known compounds, processes and methods used for manufacturing a 
particular product, new and/or improved manufacturing equipment and new and/or improved 
drug delivery mechanisms or technologies. The list is by no means exhaustive and not all of 
the above are patentable in all countries. 
The novelty requirement 
An invention is new (or novel) if it does not form part of the prior art. The prior art is, in 
general, all the knowledge that has been made available to the public prior to the filing date 
(or priority date) of the relevant patent application or (in the United States) prior to when the 
invention was "made". The definition of "prior art" differs from country to country. In many 
countries, any invention made available to the public anywhere in the world in written form, 
by oral communication, by display or through use constitutes the prior art. Thus, in principle, 
the publication of the invention in a scientific journal, its presentation in a conference, its use 
in commerce or its display in a company's catalogue before the filing date (or priority date) of 
the application claiming that invention would constitute acts that could destroy the novelty of 
such invention and render it not patentable. 
It is important to note, however, that in some countries, there is a grace period (usually of 6 
or 12 months from the public disclosure of the claimed invention by the inventor) during 
which an applicant may file an application without the novelty being destroyed by such 
disclosure. 
The inventive step/non-obviousness requirement 
An invention is considered to involve an inventive step (or to be non-obvious) when, having 
regard to the prior art, the invention would not have been obvious to a person skilled in the 
particular field of technology. The non-obviousness requirement is meant to ensure that 
patents are not granted on developments that a person skilled in the relevant art could easily 
deduce from what already exists. 
Industrial applicability/utility requirement 
To be patentable, an invention must be capable of being used in industry (or meet the 
utility requirement). This means that the invention cannot be a mere theoretical phenomenon, 
but it must be useful and provide some practical benefit. The term "industry" is used in the 
broad sense, meaning anything distinct from purely intellectual or aesthetic activity, and 
includes, for example, agriculture. In biotechnology, the utility requirement has become 
particularly important in the context of the patenting of genetic sequences over which 
possible industrial applications are unclear. Some countries require that the utility be well 
established and asserted for the claimed invention in a specific, substantial and credible 
manner. 
The disclosure requirement 
According to the applicable national or regional legislation of most countries a patent 
application must disclose the invention in a manner sufficiently clear and complete for the 
invention to be carried out by a person skilled in the specific technical field (enabling 
disclosure requirement). For example, a patent application for a new pharmaceutical product, 
must include enough practical information so that anyone familiar with the relevant technical 
field is able to follow the indicated steps and replicate and produce an effective copy of it. In 
some countries, patent legislation requires the applicant to disclose the "best mode" for 
practicing the invention. For inventions involving microorganisms, many countries require 
that, if the microorganism is not accessible to the public and the claimed invention cannot be 
described in such a way to comply with the enabling disclosure requirement without having 
access to that microorganism, such microorganism be deposited at a recognized depositary 
institution, which is capable of maintaining the microorganism in a live culture for a 
prescribed period of time. 
Patents in the life sciences 
To comply with requirements under the TRIPS Agreement of the World Trade Organization, 
most countries allow for the patenting of microorganisms and, as explained above, often 
require the deposit of a sample of the microorganism at a recognized depositary institution 
when necessary to comply with the enabling disclosure requirement. Some countries exclude 
plants and animals (other than microorganisms) from patentability. Biological materials 
that have been purified and isolated from their natural environment or produced by means of 
a technical process are patentable in many jurisdictions. National patent law in many 
countries may also list some specific types of inventions that are excluded from patentable 
subject matter, such as processes for cloning human beings or processes for modifying the 
germ line genetic identity of human beings. 
Depending on the country, plant varieties are protected either by the patent system, by a sui 
generis protection system for new varieties of plants or by a combination of the two. 
Patents on improved variations and new uses 
In many countries, improvements made to existing products are patentable, as are also new 
uses of a patented product, provided all the patentability requirements are met. In the 
pharmaceutical industry, it is not uncommon for companies to file patent applications for new 
therapeutic indications of a known drug. But such protection is not available in all 
jurisdictions. In addition, companies often file applications on new formulations or delivery 
methods of a drug, new and improved manufacturing processes, reduced dosage regimens, 
new versions of the active compound or other variations that meet the patentability 
requirements. 
(f) Layout Designs of Integrated Circuits 
India is a signatory to the international agreement administered by WIPO on this subject 
known as the Washington Treaty. The main obligations of the Washington Treaty are also 
incorporated in the TRIPS Agreement with some enhancement and cover the protection of 
the intellectual property in respect of lay-out designs that are original in the sense of being the 
result of their creator's own intellectual efforts. The obligations include national treatment to 
foreign right holders and a term of protection for 10 years. A Bill in this regard was 
introduced in the Parliament in December 1999 and is awaiting passage.  
 
 
(g) Protection of undisclosed information 
The Agreement provides in this area that natural and legal persons shall have the possibility 
of preventing information lawfully within their control from being disclosed to, acquired by 
or used by others without their consent in a manner contrary to honest commercial practices. 
Further, parties are required to protect against unfair commercial uses, undisclosed or other 
data obtained as a condition of approving the marketing of pharmaceutical or of agricultural 
chemical products. 
INDIAN PHARMACEUTICAL INDUSTRY 
The  Indian  pharmaceutical  sector  has  come  a  long  way,  being  almost  non-existent  
before 1970  to  a  prominent  provider  of  healthcare  products,  meeting  almost  95  per  
cent  of  the country's pharmaceuticals needs.   
 The Industry today is in the front rank of India’s science-based industries with wide ranging 
capabilities in the complex field of drug manufacture and technology. It ranks very high in 
the third world, in terms of technology, quality and range of medicines manufactured. From 
simple  headache  pills  to  sophisticated  antibiotics  and  complex  cardiac  compounds,  
almost every type of medicine is now made indigenously.   
 Playing a key role in promoting and sustaining development in the vital field of medicines, 
Indian  Pharma  Industry  boasts  of  quality  producers  and  many  units  approved  by 
regulatory authorities in USA and UK. International companies associated with this sector 
have stimulated, assisted and spearheaded this dynamic development in the past 53 years and 
helped to put India on the pharmaceutical map of the world.   
 The  Indian  Pharmaceutical  sector  is  highly  fragmented  with  more  than  20,000  
registered units  with  severe  price  competition  and  government  price  control.  It  has  
expanded drastically in the last two decades.   
 There are about 250 large units that control 70 per cent of the market with market leader 
holding  nearly  7  per  cent  of  the  market  share  and  about  8000  Small  Scale  Units  
together which  form  the  core  of  the  pharmaceutical  industry  in  India  (including  5  
Central  Public Sector Units). These units produce the complete range of pharmaceutical 
formulations, i.e., medicines  ready  for  consumption  by  patients  and  about  350  bulk  
drugs,  i.e.,  chemicals having therapeutic value and used for production of pharmaceutical 
formulations.   
 Following  the  de-licensing  of  the  pharmaceutical  industry,  industrial  licensing  for  
most  of the drugs and pharmaceutical products has been done away with. Manufacturers are 
free to produce any drug duly approved by the Drug Control Authority. Technologically 
strong and totally  self-reliant,  the  pharmaceutical  industry  in  India  has  low  costs  of  
production,  low R&D  costs,  innovative  scientific  manpower,  strength  of  national  
laboratories  and  an increasing balance of trade.  
The total Indian production constitutes about 13 per cent of the world market in value terms 
and, 8 per cent in volume terms.   
 The per capita consumption of drugs in India, stands at US$3, is amongst the lowest in the 
world, as compared to Japan- US$412, Germany- US$222 and USA- US$191.  
Current Status4  
India's US$ 9.4 billion pharmaceutical industry is growing at the rate of 14 percent per year. 
It   is   one   of   the   largest   and   most   advanced   among   the   developing   countries.  
The Indian pharmaceutical industry can reach a market size of US$ 11.6 billion by 2009. 
A beginning has been made with the signing of General Agreement on Tariffs and Trade in 
January  2005  with  which  India  began  recognizing  global  patents.  Soon  after,  the  
Indian pharmacy  market  became  a  sought  after  destination  for  foreign  players.  Foreign  
direct investment into the  country’s  pharmacy  industry touched  US$  172  million  during  
2005-06 having grown at a CAGR of 62.6 per cent during the period beginning 2002-06.   
 The sector recorded strong growth in the second quarter ended September 2006, driven by 
launch of new generic drugs with 180 days exclusivity period in the US market. The top ten 
pharmacy companies reported an impressive 57 per cent growth in consolidated net profit at 
US$  314.3  million,  as  against  US$  200.7  million  in  the  same  quarter  of  the  previous  
year, while consolidated net sales were up 51 per cent at US$ 1.7 billion. 
 
Company Profit( per cent) 
Ranbaxy Labs 167.2 
Dr Reddy’s Labs 65.8 
Cipla 5.2 
Nicholas Piramal 473.9 
Sun Pharma 35.8 
Lupin 26.8 
Cadila Healthcare 66.4 
Torrent Pharma 313.7 
Glenmark 74.5 
Biocon 26.1 
There are 74 U.S. FDA-approved manufacturing facilities in India, more than in any other 
country  outside  the  U.S,  and  in  2005,  almost  20  per  cent  of  all  Abbreviated  New  
Drug Applications (ANDA) to the FDA were filed by Indian companies.  
Growth in other fields notwithstanding, generics is still a large part of the picture. London 
research company Global Insight estimates that India’s share of the global generics market 
will have risen from 4 per cent to 33 per cent by 2007.  
 The focus of the Indian pharma companies is also shifting from process improvisation to 
drug discovery and R&D. the Indian companies are setting up their own R&D setups and are 
also collaborating with the research laboratories like CDRI, IICT etc. 
Emerging Trend 
The  Indian  pharmaceutical  industry  is  now  discovering  new  opportunities  of  growth  in 
clinical research, contract research, manufacturing and innovation opportunities. This path 
can lead the Indian pharmaceutical industry to huge success endeavors. 
Indian Pharmaceutical Industry: Post 2005 scenario  
 •    Global pharmacos expected to launch 200-250 new drugs over next 8-10 yearstotaling an 
estimated US$ 3-5 billion  
•    FDI  inflow  grew  over  six  fold  from  US$  60.7  mn  in  2003  to  US$  340  mn,  
infiscal year 2004  
•    Bristol Myers Squibb, Boehringer Ingelheim and Eisai without Indian presenceearlier, 
have made recent foray  
•    Indian firms tying up with foreign  companies to in-license drugs 
Research & Development4 
 Research  &  Development  is  the  key  to  the  future  of  pharmaceutical  industry.  The 
pharmaceutical advances for considerable improvement in life expectancy and health all over 
the world are the result of a steadily increasing investment in research. There is considerable 
scope for collaborative R & D in India. India can offer several strengths to the international R 
& D community. These strengths relate to availability of excellent scientific talents who can 
develop combinatorial chemistry, new synthetic molecules and plant derived candidate drugs. 
                                         
The R & D expenditure by the Indian pharmaceutical industry is around 1.9 per cent of the 
industry’s   turnover,   which   is   a   little   low   as   compared   to   foreign   research   based 
pharmaceutical companies. However, now that India is entering into the Patent protection 
area, many companies are spending relatively more on R & D.   
 When it comes to clinical evaluation at the time of multi-center trials, India is providing a 
strong base considering the real availability of clinical materials in diverse therapeutic areas. 
According  to  a  survey  by  the  Pharmaceutical  Outsourcing  Management  Association and 
Bio/Pharmaceutical    Outsourcing    Report,    pharmaceutical    companies    are    utilizing 
substantially the services of Contract Research Organizations (CROs).  Indian 
Pharmaceutical Industry, with its rich scientific talents, provides cost-effective clinical trial 
research.  It  has  an  excellent  record  of  development  of  improved,  cost-beneficial 
chemical  syntheses  for  various  drug  molecules.  Some  MNCs  are  already  sourcing these 
services from their Indian affiliates.   
Domestic Demand  
rowth potential. Factors listed below determine the rising 
demand for pharmaceuticals.   
•    The growing population of over of a billion   
•    Increasing income   
•    Demand for quality healthcare service  
se  patterns,  and  increased  demand  for 
new medicines to combat lifestyle related diseases  
ulations market is around 
Rs160 billion and it is growing at 10 per cent per annum. 
                                        
The industry has enormous g
•    Changing  lifestyle  has  led  to  change  in disea
More than 85 per cent of the formulations produced in the country are sold in the domestic 
market.  India  is  largely  self-sufficient  in  case  of  formulations.  Some  life  saving,  new 
generation under-patent formulations continue to be imported, especially by MNCs, which 
then market them in India. Overall, the size of the domestic form
 
Demand for drugs for treatment of lifestyle-related diseases such as diabetes, cardiovascular 
diseases, and  central  nervous  system  are  on  the  increase.  There  are  around  700,000 
new cases of cancer each year and total of around 2.5 million cases. It is estimated that there 
are around  40  million  people  in  India  with  diabetes  and  the  number  is  rising,  5.1 
million HIV/AIDS patients, and 14 million tuberculosis cases. According to industry reports, 
while the  Indian  
 
pharmaceutical  industry  witnessed  a  growth  of  7  percent,  the  cardio-
vascular segment recorded 15 to 17 percent growth and anti-diabetes segment of over 10-12 
percent growth.   
    
Exports  
 Over 60 per cent of India’s bulk drug production is exported. India’s pharmaceutical exports 
are to the tune of Rs87 billion, of which formulations contribute nearly 55 per cent and the 
rest 45 per cent comes from bulk drugs. In financial year 2005, exports grew by 21 per cent.  
The Indian pharmaceutical market has been forecasted to grow to as much as US$ 25 billion 
by  2010  as  per  Organization  of  Pharmaceutical  Producers  of  India  (OPPI)  estimates. 
However,  Espicom’s  market  projections  forecast  more  modest  but  stable  annual  market 
growth of around 7.2 per cent, putting the market at US$ 11.6 billion by 2009.  
Revenue from Export- India accounts for less than two per cent of the world market for 
pharmaceuticals, with an estimated market value of US$10.4 billion in 2007 at consumer 
prices, or around US$9 per capita. India  currently  represents  just  U.S.  $6  billion  of  the  
$550  billion  global  pharmaceutical industry but its share is increasing at 10 percent a year, 
compared to 7 percent annual growth for the world market overall. Also, while the Indian 
sector represents just 8 percent of the global  industry  total  by  volume,  putting  it  in  fourth  
place  worldwide,  it  accounts  for  13 percent  by  value,  and  its  drug  exports  have  been  
growing  30  percent  annually.  Cipla, Nicholas  Piramal,  Ranbaxy,  Zydus  Cadila,  Dr.  
Reddy’s are  the  few  Indian  pharmaceutical companies, which are known at the global level 
due to their quality products. 
                   
 
BIOTECHNOLOGY AND ITS GROWING IMPORTANCE 
Biotechnology is    a    field    of    applied biology that    involves    the   use    of    living   
things in engineering, technology, medicine,  and  other  useful  applications.  Modern  use  
of  the  term includes genetic engineering as well as cell- and tissue culture technologies.  The  
concept  encompasses  a  wide  range  of  procedures  (and history)  for  modifying  living 
organisms according to human
 
 purposes - going back to domestication of animals, cultivation 
of plants, and "improvements" to these through breeding programs that employ artificial 
ces  is also  
selection and hybridization.    
The United Nations Convention on Biological Diversity defines biotechnology as: "Any  
technological  application  that  uses  biological  systems,  living  organisms,  or  derivatives 
thereof, to make or modify products or processes for specific use." Biotechnology  draws  on  
the  pure  biological  sciences  (genetics, microbiology, animal  cell culture, molecular  
biology, biochemistry,  embryology, cell  biology)  and  in  many  instan
dependent  on  knowledge  and  methods  from  outside  the  sphere  of  biology  (chemical 
engineering, bioprocess engineering, information technology, and biorobotics).   
Conversely, modern biological sciences (including even concepts such as molecular ecology) 
 
niques,  processes  and  procedures  has  
arisen  to  such  an  extent  because  of the advance in technologies and the scientific 
f the emerging spheres 
and technologies in India as well on a global level. 
ological products and services has been noticed over the last 
decade in India. The two significant factors, which lie at the base of India‘s biotechnology 
are intimately entwined and dependent on the methods developed through biotechnology and 
what is commonly thought of as the life sciences industry.  
Biotech is emerging as a sector witnessing exponential growth witnessed in sub-sectors such 
as Bio-informatics sector, Industrial Biotech Sector, Agri-Biotech Sector, Research Services 
Sector, Bio-Suppliers and most importantly one of the main applications of Bio-technologies, 
the Bio-Pharmaceutical Sector.  Since  the  existence  of  the  growing  Biotechnology  
industry  cannot  be ignored hence it becomes imminent that large-scale investment also takes 
place for the required purpose of Research and Development (R&D) in this   sector.  
Presently,   the   need   for biotechnological  tech
discoveries and inventions. Hence Bio-technology has become one o
PRESENCE OF THE BIOTECHNOLOGY SECTOR IN INDIA 
There  appears  to  be  a  common  trend  that  economies  worldwide  as  well  as  the  Indian  
markets have  attracted  major  players  in  the  field  of  biotechnology.  The  rising  tide  of  
firms  dealing  in Biotechn
potential, are the scientific and technical pool of human resources and secondly the rich 
biodiversity of the country6. 
 Since India depicts an interesting demographic profile and a large agricultural base, India 
being mainly an agrarian economy, it also affords a large market base for new biotechnology 
products since being a  developing  economy  it  has  a  wide  scope  for  the  utilization  and  
the  implementation  of  these resources  because  of  its  cost  competitive  manpower,  well  
developed  and  integrated  scientific infrastructure and is globally recognized as a producer 
of low cost, high quality bulk drugs and formulations and other biotech products and services 
which holds a promising market7. As per an authentic survey conducted in the years 2003-04 
it was deduced that the presence of the  biotech  industry  in  India  was  approximately  
worth  US$  720mn.  This sector showed promising returns and a high growth factor hence 
subsequent surveys and studies enumerated a growth by 39%. This could be witnessed in the 
years 2007-08, as this Sector had become one of the  fastest  growing  and  emerging,  
technological,  knowledge-based  industries  showcasing  a turnover of almost US$ 2.13 
 development and advancement of the country. It is also 
predicted by market analysts and economic advisors that an approximate increase in the total 
d an 
 today they produce more than 250 
bulk drugs, emphasizing on import substitution and use of indigenous raw materials. At 
lty and utility, vide Bishwanath 
Prasad Radhey Shyam v.Hindustan Metal Industries Once an invention is patented the 
billion and further in 2008-09, the biotechnology industry in India was estimated to be worth 
US$ 2.51 billion8. 
Presently, India holds 2% of the market share in the global biotech sector as it has the 
appropriate market and base for the rapid growth and evolution of this industry. This may 
play a cardinal role in the economic
worth of this industry would reach upto US$ 4.5 billion by the year 2010 in India an
employment creation of 1 million.   
INTELLECTUAL PROPERTY RIGHTS AND THE CHALLENGES TO INDIAN 
PHARMACEUTICAL INDUSTRY9 
The Indian pharmaceutical industry has changed remarkably over the last 50years, from 
being traders in imported drugs in the fifties, to major bulk drug producers by the eighties. 
During this transitional period Indian pharmaceutical units have learnt the technology of bulk 
drug production by their own research and adaptation, and
present the Indian pharmaceutical industry has about 300 large units, 1700 medium-size units 
and about 8000 small-scale units throughout the country. 
The Indian law on this subject is contained in the Patents Act, 1970 (a law made by the 
Indian Parliament) as amended from time to time. In pharmaceutical industry what is 
patentable is an invention for making a product, and not a discovery in the field of 
fundamental science. In a discovery nothing new is created. On the other hand, an invention 
is creation of a new entity, or a new process, though this usually involves utilization of 
scientific discoveries. The basic requirement for patentability under the Patents law is that the 
invention should be new and useful, that is, it must have nove
patentee gets exclusive right to use it, though he may sell or lease it to another. Infringement 
of the patent can be prevented by an injunction in a civil suit. 
TRIPs, the Agreement on Trade-Related Aspects of Intellectual Property Rights is an 
International treaty by the World Trade Organization (WTO) which sets down minimum 
standards for most forms of intellectual property (IP) regulation within all member countries 
of the World Trade Organization. It was negotiated at the end of the Uruguay Round of the 
General Agreement on Tariffs and Trade (GATT) treaty in 1994. After India signed the 
General Agreement on Trade and Tariff (GATT) and the Trade Related Aspects of 
Intellectual Property Rights Agreement, 1994 (TRIPS) and became a member of the World 
Trade Organization (WTO). As India is a signatory to the TRIPS Agreement and is a member 
of WTO, the Patents Act is amended in 2005 to make it confirm to these international 
agreements. Under Article 70(8)(9) of the TRIPS Agreement regarding pharmaceutical 
(a) To recognize in principle all kinds of inventions in the area of pharmaceutical and 
(b) To provide a mechanism by which applications can be filed for new inventions as 
(c) To apply the test of patentability as laid down in the Agreement irrespective of the law of 
(d) To provide patent protection for a period of 20 years, from the date of filing once the 
(e) In the case of product patent applications in these areas, grant exclusive marketing rights 
s shorter. 
ber country; 
industry, India has the following obligations: 
agricultural chemical products in accordance with Article 27 of the Agreement. 
understood in Article 27 in these areas from 1-1-1995. 
the country on the date of filing, at the time when patent is granted or rejected. 
parties decide to grant the patent. 
for five years or until patent is granted or rejected, whichever period i
Granting of exclusive marketing rights is subject to three conditions: 
(i) product patent for the invention has been granted by another mem
(ii) market approval is obtained in such other member country; and 
(iii) market approval from the country/member granting exclusive marketing right is granted. 
Before the recent amendment Section 5 of the Indian Patents Act, 1970 Expressly prohibited 
product patents and only permitted process patent. After the implementation of TRIPS, the 
Patents (Amendment)Act, 2005 repealed it and therefore gave way to product patents as well. 
The difference between process patent and product patent is that under a process patent, 
medicine or drugs which have been patented can be manufactured by another manufacturer 
but by using a different process. However, in a product patent drugs which have been 
patented cannot be manufactured by any process. Thus, product patent is a much stringent 
restriction than process patent. In consequence of India signing the TRIPS Agreement and 
WTO India accepted the product patent from 1-1-2005 in accordance with the obligation 
under Article 27(1) of the TRIPS. It is open to a country signing the TRIPS Agreement to 
exclude from patentability inventions which are necessary to protect morality, order or health 
or avoid serious prejudice to the environment, but such exclusion can only be in areas where 
the majority of member States are also prohibiting the commercial exploitation and denying 
protection. 
The implementation of the TRIPS Agreement will give rise to factors that can put access to 
medicines out of reach for millions of people in the developing world. The TRIPS Agreement 
obliges WTO Members to adopt and enforce high standards of intellectual property rights 
protection, which were derived from the standards used in developed countries. Conforming 
to TRIPS – by recognizing and strengthening protection of intellectual property rights over 
pharmaceutical products and processes – will cause problems for developing countries. 
Implementation of the TRIPS Agreement may lead to high drug prices, low access to 
medicines and a weakening of pharmaceutical industries in the developing countries. It is 
feared that patent protection for pharmaceutical products and processes will have the effect of 
reducing or eliminating competition from generic production of medicines. There are about 
10 industrialised countries with the pharmaceutical industry and research base, capable of 
developing new chemical entities or new medicines. The multinational drug companies in 
these countries own most of the pharmaceutical technologies and products through patents. 
The minimum term of 20-year patent protection required by TRIPS effectively allows a 
pharmaceutical company a monopoly over the production, marketing and pricing of patent 
protected medicines. It will be able to keep the price of the drug high during the protection 
period, free from competition. By virtue of TRIPS protection, no generic equivalent can come 
into the market until expiry of the 20 years, denying patients cheaper alternatives. Domestic 
manufacturing of pharmaceutical products in developing countries will come to a standstill. 
Developing countries are able to produce new medicines by a process of reverse engineering; 
that is, researchers in developing countries may develop a new process different from the 
process invented (and protected by patent) to manufacture the new medicine or chemical 
entity. Reverse engineering is possible only in countries where the patent law protects 
processes but not products. The TRIPS Agreement extends the scope of patent protection to 
both products processes. It would therefore be possible to apply for patent rights over 
products for 20 years, and thereafter, further periods of 20 years each could be applied for 
products covered by patented processes. Developing country pharmaceutical producers will 
find themselves pushed out of the market, having to compete with the large MNCs. For the 
smaller producers in the developing world, which specialise and depend on manufacturing 
cheaper generic alternatives, this would no longer be possible at least, until the expiry of the 
20-year period. The TRIPS Agreement further requires patents to be granted, regardless 
whether the products are imported or locally produced. The means that patent holders can 
merely import their product, without having to work the patent in the country granting the 
right. This will mean that a MNC can supply global markets under the patent monopoly, 
exporting the finished product instead of transferring technology or making foreign direct 
investment. This is contradictory of the argument of TRIPS proponents that strict patent 
regimes will increase the flow of technology and investment into developing countries. The 
TRIPS Agreement, in its present form, contains certain provisions that can be used to limit 
patent rights. These limitations or exceptions are to be effected through national legislation, 
in order to curb abuses of intellectual property rights and anti-competitive practices, and 
generally, to offset the negative impact of patent monopolies. Two of the most important 
measures include the right of government to grant compulsory licenses and the application of 
the principle of exhaustion of intellectual property rights, which allows for parallel 
ttern of the 
National Institute of Pharmaceutical Education and Research (NIPER). The policy aims at 
importation of patented products. 
National Pharmaceutical Policy, 2006 Announced 
The National Pharmaceutical Policy, 2006 has been announced, it is focusing on research and 
drug development with clinical trials. The policy lays emphasis on developing human 
resources in pharmaceutical sciences by opening more institutions on the pa
providing a better access to anti-cancer and anti-HIV/AIDS drugs to the patients. 
Hon,ble Minister Shri Paswan said the draft National Pharmaceutical Policy, 2006 seeks to 
rationalise the excise duty on pharmaceuticals. It also seeks to streamline the system of bulk 
procurement of drugs by the Government besides promoting the generic medicines. The 
Minister said consumer awareness campaigns would be launched to educate the masses on 
the new policy. Drugs would be made available to the poor, especially the families living 
below the poverty line. He said the new policy encourages production of critical bulk drugs in 
India with emphasis on good manufacturing practices. There would be a Settlement 
Commission for settling old dues under the Drugs (Prices Control) Order, 1979. A Drug Price 
Monitoring Awareness and Accessibility Fund (DPMAA Fund) would be set up along with 
pharma parks. Shri Paswan said the policy lays greater thrust on pharma exports and on 
improving the retail system for an efficient network for distributing drugs. A Pharmaceutical 
Advisory Forum would be set up at the national level besides an advisory committee in the 
National Pharmaceutical Pricing Authority(NPPA) at its head office and five in different 
also been proposed. He said the raw material cost would be obtained 
from the manufacturers, central public enterprises in the pharmaceutical sector, import data 
Govt. disclosed that the Maximum Allowable Post-manufacturing Expenses (MAPE), 
t over the manufacturing cost, is proposed to be revised as follows: 
(b) 50% additional MAPE for R&D intensive companies which fulfill the laid down 
 74 drugs under price control MAPE would continue to remain at 100% for 
one year in order to avoid a sudden increase in prices. It would be increased thereafter on the 
(d) Based on the given percentage of MAPE, prices would be fixed for all drugs in the cost 
regions. These would be headed by the NPPA Chairman. 
In addition to the existing 74 drugs and their formulations, the 354 drugs with specified 
strength as mentioned in the National List of Essential Medicines (NLEM), 2003 have also 
been included in the draft Pharmaceutical Policy. Apart from the cost plus method, other 
systems of price control like negotiated prices, differential prices, reference prices and bulk 
purchase price have 
and market sources. 
presently 100 per cen
(a) 150% in general 
standards. 
(c) For existing
above pattern. 
plus price control system.  
(e) Maximum Retail Price (MRP) would be inclusive of all taxes as in the case of all other 
packaged commodities. 
(f) Some exemptions have been provided for certain drugs from the price control-new drugs 
developed in India through product patent, process patent and new drug delivery systems 
would be exempted from price control for 5 years. This will boost R&D in India. 
Simultaneously, vaccines and biological drugs, drugs for sale to hospitals only, drugs whose 
uterization and better monitoring. 
(j) Drugs (Price Management and Distribution) Act to be enacted for effective regulation of 
(l) Change in the name of Department of Chemicals and Petrochemicals to reflect 
) Draft policy along with Cabinet Note has been circulated to all Departments for their 
comments. On receipt of their comments it would be put up before the Cabinet. 
 
 
MRP is at Rs. 1 per capsule / tablet and generic formulations fulfilling the prescribed norms 
would be exempted. 
(g) A new Drugs (Prices Control) Order would be issued under the Essential Commodities 
Act 1955 to replace the existing DPCO, 1995. 
(h) Re-structuring and strengthening of the National Pharmaceutical Pricing Authority 
(NPPA) – greater comp
(i) Price Monitoring Cells in the State Drug Controller Offices with funding from 
Government of India. 
drug prices and for handling health emergencies – it will also provide compounding of minor 
offences. 
(k) Trade Margins on generic-generic drugs, would be fixed (15% – wholesalers and 35%-
retailers). 
Pharmaceuticals also (Name proposed is – Department of Chemicals, Petrochemicals and 
Pharmaceuticals). 
(m
INTELLECTUAL PROPERTY RIGHTS AND BIOTECH INDUSTRY 
In India, the pharma industry is one of the first to reap the benefits of biotechnology. Human 
health biotechnology products account for about 60 percent of the domestic market, while 
bio-drugs, vaccines and diagnostics have significant market shares as well. Consequently, 
Indian pharma is beginning to benefit from enhanced IP protection of their products. An 
example is Ranbaxy's NDDS for ciprofloxacin that it licensed to Bayer for $65 million plus 
royalties. Other Indian research-based companies have earned about $70 million from R&D 
novation and facilitating 
technology diffusion has been addressed with substantial progress in terms of support for 
ing the potential and relevance to the needs of 
society, the Department of Biotechnology (DBT) has emphasised the development of all 
iotechnology. 
biotechnology. In contrast, most developing countries do not have strong IPR regimes and 
milestone payments. 
Intellectual Property (IP) is central to the biotechnology industry, and brings with it a 
dimension, facilitating collaborative activity, whether it is a drug discovery or clinical or 
market-related trials. Essentially, collaborative activity is the synergy between India's ability 
to provide conditions for research, clinical trials and development, technological lead and 
capital availability in developed nations. The successful translation of these synergies into 
commercially viable applications and marketable products critically depends on the 
compatibility of regulations that deal with the registration and protection of intellectual 
property, originating from the collaborative process. Affordability and accessibility to the 
products of biotechnology are also the two key factors central to the advancement of this 
sector. Policies that foster a balance between sustaining in
R&D, human resource generation and infrastructure development. 
Over the past decade, India has shown excellence in scientific performance as evidenced by 
number and quality of publications made each year in international journals. However, its 
technological and commercial performance is low as indexed by the number of patents issued 
per unit of investment made in R&D. Realis
facets of IPR with relation to b
Importance of IP protection 
A streamlined and efficient patent protection, in addition to the industry's maturing 
relationship with capital markets are the hallmarks of America's global leadership in 
suffer negative effects of "brain drain". The reason being, lack of effective copyright laws, 
which force scientists and technicians to immigrate to countries, where their research is 
protected from unfair exploitation by competitors.  
cial benefits," notes the CEO of a 
prominent pharmaceutical company, based in Singapore.  
Global IP regulations 
ria - being novel, involving an inventive step and being 
capable of industrial application.  
 protect public order, human, 
animal and plant welfare, and to avoid environmental damage. 
Both Japan and Mexico saw a tripling of US pharmaceutical investments and R&D after they 
improved patent laws. In fact, over the past years, the stumbling block for global investors, 
looking for tie-ups with Indian firms has been the perception that India's IPR norms are too 
lenient. "The prime reason Singapore is chosen over India is because they protect Intellectual 
Property Rights. Companies take their R&D and clinical trial operations to Singapore 
because they see clarity in regulation, besides other finan
Even though, the WTO TRIPS agreement provides a foundation for IPR protection, 
enforcement is lacking in many parts of the world. The basic obligation in the area of patents 
is that inventions in all fields of technology, whether products or processes, shall be 
patentable if they meet three crite
Additionally, a patent can be granted for any invention that meets the patentability conditions 
in all fields of technology, irrespective of the place of invention. Over and above, in the 
general security exception, which applies to the entire TRIPS Agreement, only specific 
exclusions are permissible from the scope of patentability. Such exclusions span research 
areas, whose commercial exploitation should be prevented to
Biotechnology patent applications experience numerous restrictions, primarily, due to the 
undefined scope and complex nature of the technology. Deciding the scope of patent 
protection for inventions is a difficult task, as it raises a number of technical and ethical 
issues. To begin with, biotechnology is an intimidating amalgamation of biology and 
chemistry and claim interpretations. They force a judge or patent examiner to grapple with 
rather fundamental issues, such as the significance of the term 'human' when describing a 
protein. Next, it raises important policy questions, such as, the degree to which a legal 
monopoly should be granted to an innovator, whose significant contribution could be 
diminished by the consequent development of a competitor product or technique.  
Article 27 of TRIPS agreement concerns the availability, scope and use of IPR in making 
distinctions between material produced by biological processes and by non-biological routes; 
only the latter is considered patentable. Natural material of any kind is not patentable and 
article 27(3) (b) makes it clear that member states are entitled to exclude plants and animals 
but not micro-organisms from the scope of patentability. However, it is unclear whether 
TRIPS permits member states to exclude biological substances like genes and cells. 
Currently, two schools of thought exist. The first school states that there is no scientific basis 
to support the patenting of genes and genomes, which are discoveries at best, while the 
second school states that characterisation of genes is not straightforward, so it does constitute 
an inventive step and therefore should be patentable. However, despite the apparent 
controversy, British Prime Minister Tony Blair initiated an Anglo-American agreement with 
President Bill Clinton to protect the 100,000 genes of the human genome, to ensure non-
harmaceutical inventions in a 
single patent application. Using an administrative process called "restriction practice," the 
ction can delay or halt the development of a promising 
therapeutic or diagnostic product. Along with this, multiple patent applications often create 
States Patent and Trademark Office is struggling to interpret 
biotechnology patent claims, and efforts are being made to reform the restriction practice 
patentability. The agreement aimed at preventing entrepreneurs profiting from gene patents 
and so the benefits of research were freely available worldwide to combat disease.  
While US companies far outpace their competitors the world over, US patent applicants 
experience tremendous problems with the inability or unwillingness of the US Patent and 
Trademark Office (USPTO) to examine biotechnology or p
USPTO forces applicants to divide the claimed technology into several different inventions, 
only one of which can be pursued in the original application.  
Few companies can devote such funds to a single technology. Small companies and start-ups, 
in particular, cannot afford the number of applications necessary to obtain complete coverage 
for their inventions. As investors and industrial collaborators refuse to invest in unprotected 
concepts, intermittent patent prote
uncertainty in the market, as aspects of a single discovery, obtain protection over a period of 
years, rather than simultaneously. 
Currently, The United 
that, in turn, would improve patent quality, efficiency and will be necessary for international 
harmonisation of rules.  
n to twenty years. 
With this change, India fulfilled part of its commitment to the international community by 
 
compared to China which ranks second), in funding given to countries outside the US by the 
omplete the legal IP framework. The National Biotech Policy provides a framework 
and strategic direction to different sectors in order to accelerate the pace of development of 
anpower, which encourages science graduates to pursue law for a better 
understanding of IPR related issues and inclusion of the same in the curriculum of law 
IP scenario in India 
India needs to implement strong patent legislation, data exclusivity, and improve IPR 
infrastructure and enforcement in order to achieve its potential as an R&D powerhouse. The 
much-delayed second amendment to India's 1970 patent law was passed in May 2002, 
welcoming the extension of pharmaceutical patent protection from seve
protecting intellectual property. The Bill, however, makes broad ambiguous allowance for 
compulsory licensing, and is unclear about patent protection for imports.  
Data exclusivity is a prerequisite to the protection of research efforts, decisions on where to 
conduct clinical trials and amount of foreign investment in the pharmaceutical and biotech 
sectors. In 1984, the US enacted the Hatch-Waxman Act, which provides a five-year data 
exclusivity for new molecular entities (NMEs). According to the US National Institutes of 
Health (NIH), lack of data exclusivity is the primary reason why India ranks ninth, (as
NIH. In 2002, China adopted data exclusivity provisions as part of its WTO ascension, which 
provides six years of protection commencing from the date of marketing approval in China.  
Indian pharmaceutical companies and researchers, especially in the biotechnological sector, 
would benefit from increased diffusion of knowledge that results from international 
partnerships and increased integration. Fortunately, data exclusivity is an administrative 
protection, which can be easily implemented without passage of legislation. Requiring the 
government to treat test data as the exclusive property of the firm that generated it, (for a 
fixed period of time), is an effective method of providing protection, while legislators draft 
laws to c
biotechnology in India over the next ten years. For the sector of IPR, the key strategic actions 
include: 
Scientific M
colleges to facilitate filing of international patents, license negotiation and dispute 
resolutions. 
Budget allowances of Rs 50 crore as Innovative Development Fund to enable research 
scientists at academic laboratories to develop scientific innovations from a concept to a form 
Given the stress under which the Indian judicial system operates and taking into account the 
Judges might not be well-versed with the technical know-how of IPR related issues, thus 
In 2005, India's Minister for Commerce and Industry, formed a Technical Expert Committee 
wn substance or discovery renders it un-patentable. Furthermore, salts, esters, 
ethers, polymorphs, metabolites, isomers, mixtures of isomers, complexes, combinations and 
is warranted in the areas 
mentioned. Early implementation of a strong pharmaceutical patent regime would strengthen 
dia's R&D sector, attract more foreign investment, and provide a basis for Indian firms to 
begin tackling diseases that have a serious effect on the country. 
 
 
that is licensable. This fund should be under the administration of the DBT and the grants 
may be capped at Rs 50 lakhs per project. 
backlog of cases, experts feel that the existing system is not efficient enough to handle IPR 
related disputes.  
fuelling a need for an arbitration council to redress IPR disputes and showcase India as the 
next hub for contract research, clinical trials and contract manufacturing. 
to investigate the patentability of new chemical entities and micro-organisms, which the 
Parliament did not consider when it passed the Patents (Amendment) Act.  
Several ambiguous provisions in the patent laws have widened the scope of opposition in 
India and one such nebulous provision is Section 3(d). This states that new forms, properties 
or use of a kno
other derivatives are considered the same substance unless their properties and efficacy differ 
significantly.  
Although India has many of the core ingredients for a successful innovation system, to 
maintain development of the biotechnology sector, progress 
In
CASE STUDY10 
Many claim that more people do not have access to life-saving drugs because of high prices 
and that patent rights both increase prices and stand in the way of getting treatment to those 
drugs 
immediately. Since their costs are minimal, they can offer their versions at a reduced price, 
In addition, those years in which a company's patented products are protected can help 
through donations. In 2003 alone, the U.S. 
pharmaceutical industry donated more than $1.4 billion in medicines and services to people 
n turn, has greatly reduced transmission of "river 
blindness" throughout West Africa by combining a spraying program and the donation of the 
 the poorest nations of the world and has increased drug 
companies' partnership with governments and with nongovernmental organizations to ensure 
that drugs reach those in need. 
who need it. Both of these claims are false. 
Drugs that cure AIDS and many other diseases are available precisely because of patent 
protection. Patent protections encourage research and development by offering the possibility 
that a pharmaceutical company's investment will be repaid, a powerful incentive to 
companies to invest millions and millions of dollars into risky research and development of 
these medications. Without patent protection, other manufacturers could copy new 
seriously hurting the ability of the company that developed the drug to recoup its costs. 
generate the funding that makes research into the next generation of drugs possible. 
Drug companies are not only doing the research that has helped so many, they are ensuring 
that drugs reach those most in need 
in more than 40 least developed countries. 
Drug companies also are helping poorer countries through a variety of innovative public-
private partnerships. These partnerships include the African Comprehensive HIV/AIDS 
Partnership in Botswana, in which the government of Botswana, the Bill & Melinda Gates 
Foundation, and the Merck Company support prevention programs, health-care access, and 
treatment of HIV/AIDS, with Merck donating two antiretroviral drugs for treatments. The 
Onchocerciasis Control Program, i
drug Mectizan by Merck & Co., Inc. 
These are but some examples of the ways in which the research-based drug industry has 
regularly lowered its prices to
Generic medicines and copycat drugs are not always the answer for those seeking an 
alternative to a patent-protected drug. Generics, independently developed drugs that contain 
the same active substance as the original brand-name drug, are marketed in accordance with 
patent law and identified either by their own brand name or by their internationally approved 
nonproprietary scientific name. Copycat drugs usually simply copy the original drug 
manufacturer in the countries with weak intellectual property protection. 
Patented drugs often have passed much more rigorous licensing requirements than so-called 
generics. Why "so-called"? Because not all drugs that claim to be so are identical and not all 
are subject to the stringent inspection process that guarantees that they contain the same 
amount of active ingredients and work in the same way. Manufacturers of some of these 
drugs have not had to invest in the extensive testing required of the research-based industry 
even before their drug can be marketed. Of course, there are many reliable manufacturers of 
generic drugs. The United States, for instance, has a thriving generic drug industry, fully 
regulated and inspected by the U.S. Food and Drug Administration. 
Building on the enormous investment already made by the research-based pharmaceutical 
industry, copycat drugs can lower drug prices, but they do nothing to guarantee that new 
drugs will be available when they are needed. Copycat drugs do nothing to ensure that 
scientific innovation translates into new treatments that may be less toxic and more effective. 
Rather, they reduce incentives to research and thus discourage new products. And make no 
mistake: The manufacturers of generic or copycat drugs are not in business to be generous; 
they, too, are reaping profits. Their profits, however, are not being used to further scientific 
knowledge and find new cures. 
Patents are not the problem that people assume them to be, either. A recent study published in 
Health Affairs found that "in 65 low- and middle-income countries, where four billion people 
live, patenting is rare for 319 products on the World Health Organization's Model List of 
Essential Medicines. Only 17 essential medicines are patentable, although usually not 
actually patented." If this large amount of life-saving drugs is either off-patent (meaning that 
the company that originally invented them no longer has an exclusive claim because the 
patent has expired) or not patented, then patents cannot be the problem in getting drugs to 
people. 
Price is not always the issue, either. When people cite prices as a problem, they often are 
comparing apples and oranges. Prices include various factors: training of health care 
personnel in the use of the drug, explanatory materials to make it safer for the consumer, even 
shipping and handling can be included or not. If one drug seems cheaper but shipping costs 
are not included, the effective cost may be identical to that of a patented drug. Certainly, a 
government-sponsored drug company can provide lower prices to the citizens of that country, 
since the government is paying a large percentage of the actual cost. 
There are issues that need to be addressed, including how to encourage even more innovation, 
especially for drugs with limited markets or which treat diseases mostly prevalent in low- and 
middle-income countries. Developed countries can offer tax incentives to encourage 
innovation in such areas, much as the Orphan Drug Bill in the United States does. (This U.S. 
law, administered by the Food and Drug Administration, deals with medications used to treat 
diseases and conditions that rarely occur. Since there is little financial incentive for the 
pharmaceutical industry to develop such medications, "orphan drug status" gives a 
manufacturer specific financial incentives to develop and provide such medications.) 
Government research dollars can be used to do basic research, as the National Institutes of 
Health does in the United States. 
Public-private partnerships are showing the way in innovation: The Medicines for Malaria 
Venture (MMV -- see "Malaria: Partnering to Find a Cure") and the International AIDS 
Vaccine Initiative (IAVI) are two good examples of such partnerships. MMV, for instance, 
has 21 drug development projects to ensure that the next generation of treatment is available 
when drug resistance overtakes current malaria treatment options. As an article in the 
Washington Post recently suggested, "These entities are in effect nonprofit virtual drug 
companies configured to discover and develop drugs and vaccines for neglected diseases." 
Cheap drugs are no bargain, if they do not cure the disease and if they contribute to drug 
resistance that may make the drug useless for everyone. Violating or bypassing patent 
protections is a short-term solution that threatens the long-term health of the world's citizens 
by removing the incentives and discouraging the innovation we need. 
 
 
CONCLUSION 
Responsibilities  and  Resources  would  make  an  important  beginning  in  the  transition  of 
efficient and effective use of pharmaceutical in building a prosperous and healthy India.  
 The  Indian  pharmaceutical  industry  shall  ensure  that  essential  drugs  at  affordable 
prices are   available to the vast population of this sub-continent and also continue providing 
employment for   millions. India shall implement all the rules and regulations, which guide, 
monitor and control the  activities  of  the  providers  of  the  healthcare  system  in  the  
country  and  shall Corporate Catalyst India    India’s Pharmaceutical Industry examine  the  
way  to bring  them  up  to  international  standards.  The government should implement the 
recommendations of Mashelkar committee and constitute the Central Drug Authority at the 
earliest. The basic course of education should be designed to ensure that the newly qualified 
pharmacist   has   the   necessary   knowledge   and   skills   to   commence   practicing 
competently in a variety of settings including community and hospital pharmacy and the  
pharmaceutical  industry.  Continuing  professional  development  must  then  be  a lifelong  
commitment  for  every  practicing  pharmacist. Concept of  National  schools of pharmacy 
should be established to develop and introduce model curriculum.  Pharmacists should 
become knowledgeable to participate in medication management and outcome monitoring. 
Pharmacy profession should orient concept of pharmacy practice at community and hospital 
pharmacies through appropriate training and compensation. The pharmacy profession will 
make the clinical trial industry in India to grow to over a billion dollars in the next five years 
and position itself as a destination of choice for CRO  services  by  way of  strict  
implementation  of  patent  laws,  single  window clearance of clinical trial protocols by 
regulatory clearances and shall accord industry status to this sector. India will emerge as a 
major global player in the field of pharmaceuticals exports and as a provider of quality 
medicines at low costs. It shall also emerge as a major player in the generic drugs    market in 
USA and Europe. India shall attain new heights in herbal drugs research in shaping Indian 
Systems of Medicine into a popular system of medicine of the future for holistic health care 
and ensuring health care for all - especially for the welfare of the poor.  
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